Publicaties

Publicatie overzicht

Johanne Rozema, Ivar van Asten, Beau Kwant, Robby Kibbelaar, Nic Veeger, Harry de Wit, Eric van Roon, Mels Hoogendoorn, on behalf of the HemoBase Population Registry Consortium. “Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes”. [published online ahead of print, 2022 Sep 21]. Eur J Haematol. 2022;10.1111/ejh.13865. doi:10.1111/ejh.13865

Johanne Rozema, Mels Hoogendoorn, Iris Potma, Inge ten Seldam, Nic Veeger, Robby Kibbelaar, Arjan van de Loosdrecht, Eric van Roon, on behalf of the HemoBase Population Registry Consortium, “Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes”. eJHaem 2022; 1-10. DOI: 10.12/jha2422

Rozema, J., Roon, E.N.v., Kibbelaar, R.E., Veeger, N.J.G.M., Slim, C.L., Wit, H.d., Hoogendoorn, M. & on behalf of the HemoBase Population Registry Consortium 2021, “Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study”, Transfusion, vol. 61, no. 10, pp. 2877-2884

Rozema, J., Hoogendoorn, M., Kibbelaar, R., Berg, E.v.d., Veeger, N. & Roon, E.v. 2021, “Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study”, Blood advances, vol. 5, no. 5, pp. 1344-1351

Oortgiesen, B.E., Kroes, J.A., Scholtens, P., Hoogland, J., Dannenberg-de Keijzer, P., Siemes, C., Jansman, F.G.A., Kibbelaar, R.E., Veeger, N.J.G.M., Hoogendoorn, M. & Roon, E.N.v. 2022, “High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study”, Supportive care in cancer, vol. 30, no. 1, pp. 271-278

J. Rozema, C.L. Slim, N.J.G.M. Veeger, R.E. Kibbelaar, H. de Wit, E.N. van Roon, M. Hoogendoorn. A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study. Transfusion Medicine 2020

Berdien E. Oortgiesen, Johanna H.M. Driessen, Mels Hoogendoorn, Robby E. Kibbelaar, Nic J.G.M. Veeger, Peter Vestergaard, Frank de Vries, Eric N. van Roon. No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study. Bone 2020

V.S. Nelson, S.N. Amini, R. Fijnheer, M.R. Schipperus. ITPBase: de registratie van de effectiviteit en bijwerkingen van behandelingen bij persisterende en chronische ITP-patiënten. NTVH 2019; 16: 329-36. Acknowledgement HemoBase foundation

H. T. van der Galiën, M. Hoogendoorn, R. E. Kibbelaar, T. van Meerten and R. S. van Rijn. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting. Letter to the Editor of Annals of Oncology. Annals of Oncology, Volume 30, Issue 1, 1 January 2019: 151–152

Berdien E. Oortgiesen, Roshna Azad, Marc H. Hemmelder, Robby E Kibbelaar, Nic J.G.M. Veeger, Joost C. de Vries, Eric N. van Roon, Mels Hoogendoorn. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Haematologica March 2018

Geelen IGP, Thielen N, Janssen JJWM, Levin MD, Hoogendoorn M, Visser O, Cornelissen JJ, Westerweel PE. Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival. Eur J Haematol. 2017 Oct;99(4):381-382

Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, Joosten P, Storm H, van Roon EN, Hoogendoorn M. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology. Eur J Cancer. 2017 Oct 6;86:178-185

Nijland M, Boslooper K, van Imhoff G, Kibbelaar R, Joosten P, Storm H, van Roon EN, Diepstra A, Kluin-Nelemans HC, Hoogendoorn M. Relapse in stage I(E) diffuse large B-cell lymphoma. Hematol Oncol. 2017 Oct 30. doi: 10.1002/hon.2487

van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, van de Loosdrecht AA. Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. Am J Hematol. 2017 Nov;92(11):E631-E634

Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Visser O, Cornelissen JJ, Westerweel PE. Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia. Haematologica. 2017 Nov;102(11):1842-1849

de Vries JC, Oortgiesen B, Hemmelder MH, van Roon E, Kibbelaar RE, Veeger N, Hoogendoorn M. Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study. Leuk Lymphoma. 2017 Sep;58(9):1-9

Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Valk PJM, Visser O, Cornelissen JJ, Westerweel PE. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica. 2017 Aug 31. pii: haematol.2017.175265. doi:

Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, van den Berg E, Bosga-Bouwer AG, Kibbelaar RE, Hoogendoorn M, van Imhoff GW, Kluin-Nelemans HC, Kluin PM, Nijland M. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology. 2017 Jul 21. doi: 10.1111/his.13316

B.E. Oortgiesen, E.N. van Roon, P. Joosten, R.E. Kibbelaar, H. Storm, S. Hovenga, B. van Rees, G. Woolthuis, N. Veeger, E.G. de Waal, Mels Hoogendoorn. The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. Eur. J. of Clinical Pharmacology, 2017 Jun;73(6):771-778

Boslooper K, Hoogendoorn M, van Roon EN, Kibbelaar RE, Storm H, Hovenga S, Woolthuis G, van Rees BP, Klijs B, Veeger NJGM, Kluin-Nelemans HC, de Bock GH. No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status. Cancer Epidemiol. 2017 Jun;48:110-116

Waal, E.G.d., Leene, M., Veeger, N., Vos, H.J., Ong, F., Smit, W.G., Hovenga, S., Hoogendoorn, M., Hogenes, M., Beijert, M., Diepstra, A. & Vellenga, E. “Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands”, BJH 2016, vol. 175, no. 4, pp. 661-667

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015 Dec;24(12):2895-906

Kluin PM, Langerak AW, Beverdam-Vincent J, Geurts-Giele WR, Visser L, Rutgers B, Schuuring E, Van Baarlen J, Lam KH, Seldenrijk K, Kibbelaar RE, de Wit P, Diepstra A, Rosati S, van Noesel MM, Zwaan CM, Hunting JC, Hoogendoorn M, van der Gaag EJ, van Esser JW, de Bont E, Kluin-Nelemans HC, Winter RH, Lo Ten Foe JR, van der Zanden AG. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder? J Pathol. 2015 Jul;236(3):302-14

H.M. Blommestein, D.E. Issa, M. Pompen, C. Révil, M. Hoogendoorn, P. Joosten, S.Zweegman, P.C Huijgens, C.A. Uyl-de Groot. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: Results of a population-based study. Eur J Haematol. 2014; 92(5):398-406

A. Wieringa/K. Boslooper, M. Hoogendoorn, P. Joosten, T. Beerden, H. Storm, R. Kibbelaar, G.J. Veldhuis, H. van Kamp, B. van Rees, H.C. Kluin-Nelemans, N.J.G.M. Veeger and E.N. van Roon. Comorbidity is an Independent Prognostic Factor in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) treated with R-CHOP: a Population-Based Cohort Study. BJH, 2014; 165 (4): 489-496

Karin Boslooper, Robby Kibbelaar, Huib Storm, Nic J.G.M. Veeger, Sjoerd Hovenga, Gerhard Woolthuis, Bas van Rees, Elly de Graaf, Eric van Roon, Hanneke C. Kluin-Nelemans, Peter Joosten, Mels Hoogendoorn. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in the very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leukemia&Lymphoma, 2014; 55 (3): 526-532

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oer

J. Schouten, S. Jaber, H. Ablij, R. Kibbelaar, H. Storm, P. Joosten, M. Hoogendoorn. Transparante zorg. Interne Geneeskunde 2013; 1: 8-11

Blommestein HM, Issa DE, Pompen M, Révil C, Hoogendoorn M, Joosten P, Zweegman S, Huijgens PC,  Uyl-de Groot CA. Pharmacoeconomic Evaluation of Rituximab as Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Real-World Population Based Study Cost-effectiveness of rituximab as maintenance treatment for folliculair lymphoma: results of a real world population based study. Value in Health 15(7): A421 · November 2012

Helm van der L, Canan A, Wijermans PW, Marwijk Kooy R, Schaafsma R,  Biemond BJ, Beeker A, Hoogendoorn M, Rees van BP, Weerdt de O, Wegman J, Libourel GJ, Jie GKS, Loosdrecht AA, Koedam J, Veeger NJCM, Vellenga E, Huls G. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haemotol 2011;155(5): 599-606

M. Hoogendoorn, P. Joosten, H. Storm, R.E. Kibbelaar. HemoBase: een intelligent EPD als coach voor de hemato-oncologische zorg. NTvH 2009, nr. 3; 104-109

Vijf steden, één netwerk. Joost Visser. Medisch Contact, 2005, nr. 49: 1964-7.

Start typing and press Enter to search

Shopping Cart